Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Patients may notice modest weight reduction within the first month, but clinically meaningful weight loss typically accumulates over several months
Initially developed for Type 2 diabetes, they are now a leading therapy for chronic weight management
Novo pioneered GLP-1 therapy: it launched Victoza (liraglutide) for diabetes in 2010 and then Wegovy (semaglutide 2.4 mg injection) for obesity in 2021 ( [14] ) ( [18] )
Patients may want to ask What side effects are most commonly reported Which symptoms should prompt follow up or evaluation How are tolerability concerns typically addressed According to prescribing information reviewed by the U.S
CJC-1295 works by stimulating the pituitary gland to produce more growth hormone
